Single dose regorafenib-induced hypertensive crisis

Gastrointestinal stromal tumors (GISTs) are uncommon tumors of the gastrointestinal (GI) tract. Regorafenib is a new multikinase inhibitor and is approved for the treatment of GISTs in patients who develop resistance to imatinib and sunitinib. The most common drug-related adverse events with regoraf...

Повний опис

Збережено в:
Бібліографічні деталі
Опубліковано в: :Experimental Oncology
Дата:2014
Автори: Yilmaz, B., Kemal, Y., Teker, F., Kut, E., Demirag, G., Yucel, I.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2014
Теми:
Онлайн доступ:https://nasplib.isofts.kiev.ua/handle/123456789/145356
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Single dose regorafenib-induced hypertensive crisis / B. Yilmaz, Y. Kemal, F. Teker, E. Kut, G. Demirag, I. Yucel // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 134-135. — Бібліогр.: 15 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-145356
record_format dspace
spelling Yilmaz, B.
Kemal, Y.
Teker, F.
Kut, E.
Demirag, G.
Yucel, I.
2019-01-20T19:23:45Z
2019-01-20T19:23:45Z
2014
Single dose regorafenib-induced hypertensive crisis / B. Yilmaz, Y. Kemal, F. Teker, E. Kut, G. Demirag, I. Yucel // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 134-135. — Бібліогр.: 15 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145356
Gastrointestinal stromal tumors (GISTs) are uncommon tumors of the gastrointestinal (GI) tract. Regorafenib is a new multikinase inhibitor and is approved for the treatment of GISTs in patients who develop resistance to imatinib and sunitinib. The most common drug-related adverse events with regorafenib are hypertension, hand-foot skin reactions, and diarrhea. Grade IV hypertensive side effect has never been reported after a single dose. In this report, we present a case of Grade IV hypertensive side effect (hypertensive crisis and seizure) after a single dose of regorafenib. A 54-year-old male normotensive GIST patient was admitted to the emergency department with seizure and encephalopathy after the first dosage of regorafenib. His blood pressure was 240/140 mmHg upon admission. After intensive treatment with nitrate and nitroprusside, his blood pressure returned to normal levels in five days. Regorafenib was discontinued, and he did not experience hypertension again. This paper reports the first case of Grade IV hypertension after the first dosage of regorafenib. We can suggest that hypertension is an idiosyncratic side effect unrelated to the dosage. Key Words: hypertension, regorafenib, gastrointestinal stromal tumor.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Case report
Single dose regorafenib-induced hypertensive crisis
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Single dose regorafenib-induced hypertensive crisis
spellingShingle Single dose regorafenib-induced hypertensive crisis
Yilmaz, B.
Kemal, Y.
Teker, F.
Kut, E.
Demirag, G.
Yucel, I.
Case report
title_short Single dose regorafenib-induced hypertensive crisis
title_full Single dose regorafenib-induced hypertensive crisis
title_fullStr Single dose regorafenib-induced hypertensive crisis
title_full_unstemmed Single dose regorafenib-induced hypertensive crisis
title_sort single dose regorafenib-induced hypertensive crisis
author Yilmaz, B.
Kemal, Y.
Teker, F.
Kut, E.
Demirag, G.
Yucel, I.
author_facet Yilmaz, B.
Kemal, Y.
Teker, F.
Kut, E.
Demirag, G.
Yucel, I.
topic Case report
topic_facet Case report
publishDate 2014
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Gastrointestinal stromal tumors (GISTs) are uncommon tumors of the gastrointestinal (GI) tract. Regorafenib is a new multikinase inhibitor and is approved for the treatment of GISTs in patients who develop resistance to imatinib and sunitinib. The most common drug-related adverse events with regorafenib are hypertension, hand-foot skin reactions, and diarrhea. Grade IV hypertensive side effect has never been reported after a single dose. In this report, we present a case of Grade IV hypertensive side effect (hypertensive crisis and seizure) after a single dose of regorafenib. A 54-year-old male normotensive GIST patient was admitted to the emergency department with seizure and encephalopathy after the first dosage of regorafenib. His blood pressure was 240/140 mmHg upon admission. After intensive treatment with nitrate and nitroprusside, his blood pressure returned to normal levels in five days. Regorafenib was discontinued, and he did not experience hypertension again. This paper reports the first case of Grade IV hypertension after the first dosage of regorafenib. We can suggest that hypertension is an idiosyncratic side effect unrelated to the dosage. Key Words: hypertension, regorafenib, gastrointestinal stromal tumor.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/145356
citation_txt Single dose regorafenib-induced hypertensive crisis / B. Yilmaz, Y. Kemal, F. Teker, E. Kut, G. Demirag, I. Yucel // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 134-135. — Бібліогр.: 15 назв. — англ.
work_keys_str_mv AT yilmazb singledoseregorafenibinducedhypertensivecrisis
AT kemaly singledoseregorafenibinducedhypertensivecrisis
AT tekerf singledoseregorafenibinducedhypertensivecrisis
AT kute singledoseregorafenibinducedhypertensivecrisis
AT demiragg singledoseregorafenibinducedhypertensivecrisis
AT yuceli singledoseregorafenibinducedhypertensivecrisis
first_indexed 2025-12-01T19:55:24Z
last_indexed 2025-12-01T19:55:24Z
_version_ 1850860898276605952